A Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat

NCT04144049 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
176
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Medy-Tox